Wound care billing services in Pennsylvania are navigating one of the most demanding reimbursement environments in the country right now. Pennsylvania sits under Novitas Solutions’ JH\/JL MAC jurisdiction \u2014 and Novitas is actively conducting Targeted, Probe and Educate audits on skin substitute claims. The CY 2026 Physician Fee Schedule Final Rule (CMS-1832-F) reset non-biological skin substitute reimbursement to a flat rate of $127.14 per square centimeter.<\/p>\r\n
And Highmark \u2014 the dominant commercial payer across western and central Pennsylvania \u2014 adopted the CMS flat-rate pricing methodology for non-BLA skin substitutes effective January 1, 2026, for both Medicare Advantage and commercial plans.<\/p>\r\n
If your practice is applying cellular tissue products for diabetic foot ulcers or venous leg ulcers without a Novitas-specific documentation workflow, the revenue exposure is real and it’s growing with every claim cycle.<\/p>\r\n
Pennsylvania is not a simple billing market for wound care. It has three dominant commercial payers \u2014 Highmark in western and central Pennsylvania, Independence Blue Cross in the Philadelphia metro, and UPMC Health Plan in Pittsburgh \u2014 each with distinct prior authorization requirements, documentation standards, and skin substitute reimbursement policies.<\/p>\r\n
It has a large Medicare and Medicaid population across rural Appalachian communities in the central and northeastern regions. And it sits under Novitas, one of the most actively auditing MACs in the country for wound care claims.<\/p>\r\n
Pennsylvania wound care billing<\/a> also requires managing a payer-specific product approval split that most practices aren’t tracking at the claim level. Highmark reimburses BLA-approved skin substitutes under ASP+6% methodology while applying CMS flat-rate pricing for non-BLA products.<\/p>\r\n Independence Blue Cross and UPMC Health Plan each maintain their own coverage criteria for cellular and tissue-based products. Treating these payers identically on skin substitute claims generates systematic revenue leakage on every application.<\/p>\r\n